为充分尊重投资者、提升交流的针对性，现就公司2022年度网上业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年4月26 日（星期三）下午15:00 前访问 http://ir.p5w.net/zj/或扫描下方二维码，进入 问题征集专题页面。公司将在2022年度网上业绩说明会上，对投资者普遍关注的问 题进行回答。欢迎广大投资者积极参与本次网上业绩说明会。 （问题征集专题页面二维码） 特此公告。 证券代码：002566 证券简称：益盛药业 公告编号：2023-011 吉林省集安益盛药业股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 吉林省集安益盛药业股份有限公司（以下简称"公司"）已于2023年4月19日在 巨潮资讯网（www.cninfo.com.cn）披露了《2022年年度报告》。为便于广大投资者 进一步详细了解公司情况，公司定于2023年4月26日（星期三）下午15:00-17:00在 全景网举行2022年度网上业绩说明会。本次说明会将采用网络远程方式举行，投资 ...

证券代码：002566 证券简称：益盛药业 吉林省集安益盛药业股份有限公司 投资者关系活动记录表 编号：2015-001 | --- | --- | --- | |-----------------------|----------------------------|------------------------------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 东方国际伍一支；华创证券张伟光；建信基金潘龙玲； 21 世纪 | | 人员姓名 | | 报道谢达斐；国都证券姚巍；宏道投资杨洁；吉渊投资陈杰； | | | | 天弘基金郭相博、刘盟盟；工银瑞信谭冬寒；泰达宏利庞文杰； | | | 中国证券报尹哲辉。 | | | 时间 | 2015 年 6 月 26 | 日 | | 地点 | 北京拉斐特城堡酒店会议中 ...

证券代码：002566 证券简称：益盛药业 吉林省集安益盛药业股份有限公司 投资者关系活动记录表 编号：2016-001 | --- | --- | --- | |----------------|-------------------------|----------------------------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 中航证券沈文文、成果 | | | 人员姓名 | | | | 时间 | 2016 年 11 月 3 | 日 | | 地点 | 总经理办公室 | | | 上市公司接待人 | | 总经理薛晓民、证券事务代表丁富君 | | 员姓名 | | | | 投资者关系活动 | | 本次投资者关系活动的主要内容包括：公司人参产业发展规划 | | 主要内容介绍 | | 情况及进展情况，并到人参饮片 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥194,524,452.56, a decrease of 11.04% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2022 was ¥16,521,841.90, down 30.81% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥14,750,114.65, reflecting a decline of 38.52% compared to the previous year[4] - Total operating costs decreased from ¥592,743,896.16 to ¥557,743,368.96, a reduction of approximately 5.9%[18] - Net profit attributable to shareholders decreased from ¥65,251,454.52 to ¥60,333,857.59, a decline of about 7.5%[19] - Operating profit decreased from ¥88,409,326.92 to ¥77,426,756.64, a drop of approximately 12.3%[18] - Total comprehensive income decreased from ¥74,375,675.38 to ¥65,887,086.43, a decrease of about 11.5%[19] - Basic and diluted earnings per share decreased from ¥0.1972 to ¥0.1823, a decline of approximately 7.5%[19] Cash Flow and Liquidity - The cash flow from operating activities for the year-to-date period was ¥87,206,481.59, a significant decrease of 46.50% year-on-year[4] - Cash flow from operating activities decreased from ¥163,004,140.39 to ¥87,206,481.59, a decline of about 46.6%[21] - The company's cash and cash equivalents increased by 32.00% to ¥289,992,896.36 due to improved cash flow from operations[8] - Cash and cash equivalents at the end of the period increased to ¥289,992,896.36 from ¥283,417,266.80, an increase of approximately 2.0%[22] - Net cash flow from financing activities showed a net outflow of ¥20,344,523.90 compared to a net outflow of ¥65,898,484.84 in the previous period[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,892,384,151.53, an increase of 0.98% from the end of the previous year[5] - The total assets of the company as of September 30, 2022, amounted to RMB 2,892,384,151.53, up from RMB 2,864,366,655.13 at the start of the year[15] - The total liabilities decreased slightly to RMB 665,388,413.79 from RMB 666,082,205.82, showing a marginal reduction[15] - The company's total equity increased to RMB 2,226,995,737.74 from RMB 2,198,284,449.31, reflecting an increase of approximately 1.3%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,907[10] - The top shareholder, Zhang Yisheng, holds 39.08% of the shares, amounting to 129,348,530 shares[10] Government Subsidies and Non-Recurring Gains - The company received government subsidies amounting to ¥2,314,073.95 during the reporting period, contributing to its non-recurring gains[6] Operational Metrics - Sales revenue from goods and services received cash decreased from ¥769,868,721.37 to ¥685,040,384.37, a decline of approximately 11.0%[20] - Research and development expenses increased from ¥14,891,356.12 to ¥15,482,990.67, an increase of about 3.9%[18] - Accounts receivable rose to RMB 216,225,964.18 from RMB 195,846,007.45, indicating an increase of about 10%[14] - The inventory level remained stable at RMB 1,602,331,661.55, compared to RMB 1,596,871,561.48 at the beginning of the year[14] Corporate Governance - The company is implementing a rectification plan to address issues related to shareholding disclosure, with certain shareholders no longer having shareholding proxies[12] - The company aims to resolve the shareholding proxy issues in the shortest time possible while considering the impact on the secondary market[12] Employee Compensation - The company reported a decrease in employee compensation liabilities to RMB 5,706,420.52 from RMB 7,907,392.07, indicating a reduction of approximately 28%[15]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥428,409,146.26, a decrease of 5.82% compared to ¥454,884,074.49 in the same period last year[25]. - The net profit attributable to shareholders of the listed company was ¥43,812,015.69, an increase of 5.90% from ¥41,371,047.86 year-on-year[25]. - The net cash flow from operating activities decreased by 39.79% to ¥72,426,598.89 from ¥120,294,568.26 in the previous year[25]. - The basic earnings per share increased to ¥0.1324, up 5.92% from ¥0.1250 in the same period last year[25]. - The company reported a decrease of 8.53% in net profit after deducting non-recurring gains and losses, totaling ¥32,817,432.17 compared to ¥35,876,286.87 in the previous year[25]. - The company's total revenue for the reporting period was ¥428,409,146.26, representing a decrease of 5.82% compared to the previous year[47]. - The pharmaceutical sector accounted for 82.01% of total revenue, with a year-on-year increase of 5.50% in this segment[48]. - The total profit for the first half of 2022 was CNY 87,892,527.35, compared to CNY 85,417,906.33 in the previous year, an increase of 2.9%[136]. - The company reported a net increase in cash and cash equivalents of ¥61,534,961.32 for the first half of 2022, contrasting with a decrease of ¥147,545,647.58 in the same period of 2021[142]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,888,592,843.66, reflecting a 0.85% increase from ¥2,864,366,655.13 at the end of the previous year[25]. - The company's total assets as of June 30, 2022, were CNY 2,974,259,795.98, an increase from CNY 2,935,747,364.14 at the beginning of the year[129]. - The total liabilities decreased to CNY 865,192,174.31 from CNY 898,658,750.33 at the start of the year[129]. - The inventory level was ¥1,586,034,217.18, accounting for 54.91% of total assets, showing a slight decrease from the previous year[54]. Research and Development - The company has developed 11 dosage forms and 117 varieties, with 49 products included in the National Basic Medical Insurance Drug List[38]. - The company holds 19 invention patents, 5 design patents, and 4 utility model patents, indicating a strong focus on innovation[45]. - Research and development expenses decreased by 36.99% to ¥13,327,785.79, primarily due to reduced clinical trial costs[47]. - The company has initiated research and development for new technologies aimed at enhancing product offerings[145]. - The company is focusing on enhancing its research and development capabilities to innovate new technologies and products[150]. Market and Business Strategy - The company is expanding its business model to include health foods and cosmetics, forming a complete ginseng industry chain[37]. - The company aims to leverage technological innovation and internal management to ensure sustainable development amidst a challenging market environment[33]. - The company plans to maintain its strategy of building a complete ginseng industry chain, increasing its ginseng reserves through self-cultivation and external procurement[64]. - Future guidance indicates a cautious outlook, with expectations of gradual recovery in revenue growth[145]. Social Responsibility and Governance - The company emphasizes social responsibility, focusing on environmental friendliness, resource conservation, and participation in social welfare activities[76]. - The company has implemented strict internal control systems to protect the rights of shareholders and creditors, ensuring timely disclosure of major information[77]. - The company has established a comprehensive emergency response mechanism for environmental pollution incidents, including a specific emergency plan and regular employee training[75]. - The company has not received any administrative penalties for environmental issues during the reporting period[74]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 28,525[108]. - Zhang Yisheng holds 39.08% of the shares, totaling 129,348,530 shares[108]. - The total number of shares is 330,951,600, with 69.91% being unrestricted shares[106]. - There were no changes in the number of shares held by major shareholders during the reporting period[108]. Cash Flow and Financing - The total cash inflow from operating activities was ¥390,266,026.16, while cash outflow was ¥382,315,619.37, resulting in a positive net cash flow[140]. - The company received ¥170,000,000.00 from borrowings, while cash outflow for debt repayment was ¥170,000,000.00, leading to a net cash flow from financing activities of -¥7,331,676.21[142]. - The cash flow from financing activities showed a significant decrease in cash outflow for dividend distribution, which was ¥7,265,076.21 compared to ¥16,709,623.72 in the previous year[142]. Compliance and Accounting - The financial statements are prepared based on the going concern assumption and comply with the relevant accounting standards[159]. - The company has not identified any significant doubts regarding its ability to continue as a going concern for at least 12 months from the reporting date[160]. - The financial report was approved by the board on August 25, 2022[158]. - The company adheres to the accounting policies and estimates as per the relevant accounting standards[161].

Financial Performance - The company's revenue for Q1 2022 was ¥225,540,617.25, a decrease of 1.55% compared to ¥229,097,736.43 in the same period last year[4] - Net profit attributable to shareholders was ¥27,229,639.30, down 1.93% from ¥27,765,054.54 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥19,705,067.74, representing a decline of 15.81% from ¥23,405,772.17 in the previous year[4] - Total operating revenue for the current period is $225.54 million, a decrease of 1.23% from $229.10 million in the previous period[21] - Operating profit decreased to $33.67 million, down 19.73% from $41.91 million in the previous period[22] - Net profit for the current period is $29.23 million, a decline of 12.93% compared to $33.19 million in the previous period[22] Cash Flow and Liquidity - The net cash flow from operating activities increased by 32.73% to ¥38,973,399.49, compared to ¥29,363,113.24 in the same period last year[4] - Cash flow from operating activities increased to $38.97 million, up 32.73% from $29.36 million in the previous period[26] - Cash and cash equivalents at the end of the quarter were CNY 200,989,827.14, down from CNY 219,695,016.40[17] - Cash and cash equivalents at the end of the period decreased to $200.99 million, down from $290.24 million in the previous period[27] - The company reported a net cash outflow from financing activities of $31.03 million, compared to an outflow of $12.24 million in the previous period[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,850,618,838.70, a decrease of 0.48% from ¥2,864,366,655.13 at the end of the previous year[4] - The company's current assets totaled CNY 2,208,310,379.88, slightly down from CNY 2,221,792,551.02 at the start of the year[17] - The total liabilities decreased to CNY 650,352,779.13 from CNY 666,082,205.82[19] - The company's equity attributable to shareholders increased to CNY 2,109,039,378.83 from CNY 2,081,809,739.53[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 36,823[10] - Basic and diluted earnings per share decreased to $0.0823, down from $0.0839 in the previous period[23] Expenses - Total operating costs increased to $199.83 million, up 2.03% from $194.43 million in the previous period[21] - Financial expenses rose by 98.56% to ¥2,610,477.73, primarily due to decreased interest income and increased interest expenses[8] - Financial expenses increased to $2.61 million, up from $1.31 million in the previous period[22] - Research and development expenses for the current period were $4.34 million, a decrease of 10% from $4.82 million in the previous period[21] Government Support - The company received government subsidies amounting to ¥8,400,380.57 during the reporting period[6] Accounts Receivable and Inventory - The company's accounts receivable increased by 61.76% to ¥2,922,425.05, influenced by an increase in commercial acceptance bills[8] - Accounts receivable rose to CNY 223,010,062.92 from CNY 195,846,007.45, indicating a growth of approximately 13.8%[17] - Inventory levels were reported at CNY 1,593,579,012.74, a slight decrease from CNY 1,596,871,561.48[17] Other Information - The company is addressing issues related to shareholding transparency and has implemented a plan to rectify the situation regarding shareholding disclosures[13] - The company’s short-term borrowings remained stable at CNY 397,864,988.96, compared to CNY 397,862,867.43 at the beginning of the year[18] - The company’s net profit for the first quarter of 2022 is not explicitly stated in the provided documents, but the focus on product inclusion in COVID-19 treatment guidelines suggests potential revenue growth opportunities[14]

Financial Performance - The company's operating revenue for 2021 was CNY 877,929,541.89, representing a 4.19% increase compared to CNY 842,589,907.04 in 2020[19] - The net profit attributable to shareholders for 2021 was CNY 96,020,349.90, a 19.94% increase from CNY 80,060,085.80 in 2020[19] - The net profit after deducting non-recurring gains and losses was CNY 83,970,880.18, up 27.72% from CNY 65,746,181.53 in 2020[19] - The basic earnings per share for 2021 was CNY 0.2901, reflecting a 19.93% increase from CNY 0.2419 in 2020[19] - The total assets at the end of 2021 were CNY 2,864,366,655.13, a 2.44% increase from CNY 2,796,099,005.75 at the end of 2020[19] - The net assets attributable to shareholders at the end of 2021 were CNY 2,081,809,739.53, up 4.31% from CNY 1,995,717,937.63 at the end of 2020[19] - The net cash flow from operating activities for 2021 was CNY 215,100,714.73, a 5.69% increase from CNY 203,514,966.83 in 2020[19] - The weighted average return on equity for 2021 was 4.72%, an increase from 4.08% in 2020[19] Product Development and Innovation - The company has developed a complete industrial chain for ginseng, expanding from pharmaceutical production to health products and cosmetics[31] - The company holds 117 product varieties and has 49 products listed in the National Basic Medical Insurance Drug Catalog[31] - The company has cultivated over 10,000 acres of organic non-forest ginseng, recognized as a protected ecological origin product[32] - The company has received 14 patents and established a comprehensive planting technology system for ginseng cultivation[32] - The company completed the development and filing of 30 health food products, launching 5 new products during the reporting period[42] - The company launched 14 new cosmetic products and enhanced its online sales channels, including live streaming sales[44] Market and Sales Performance - The pharmaceutical sector contributed ¥665,013,635.04, accounting for 75.75% of total revenue, with a year-on-year growth of 3.46%[46] - The online direct sales model saw a significant decline of 63.76%, dropping to ¥11,223,826.07 from ¥30,973,020.78 in the previous year[46] - The company sold 37,040,371 boxes in the pharmaceutical sector, an increase of 3.27% from 35,868,297 boxes in 2020[49] - The revenue from the cosmetics sector was ¥116,288,065.52, with a slight increase of 0.28% year-on-year[46] Research and Development - Research and development expenses increased by 32.98% to ¥20,892,630.06, primarily due to increased clinical trial costs[58] - The total R&D investment reached ¥37,584,947.77, a 13.12% increase compared to the previous year, with R&D expenses accounting for 4.28% of operating revenue[60] - The company has ongoing clinical research projects aimed at enhancing product competitiveness in the market[59] Corporate Governance and Management - The company adheres to strict governance practices, ensuring compliance with relevant laws and regulations while maintaining effective communication with shareholders[86] - The company has established a performance-based incentive and evaluation system for its senior management to align compensation with company performance[87] - The company has a robust organizational structure, with independent operation of the shareholders' meeting, board of directors, and supervisory board[91] - The company has established a performance appraisal system linking employee salaries to company performance and individual contributions[119] Social Responsibility and Environmental Compliance - The company actively engaged in social responsibility initiatives during the COVID-19 pandemic, including donations and compliance with information disclosure[45] - The company emphasizes environmental protection and has integrated energy conservation and emission reduction into its key agenda[137] - The company has not faced any administrative penalties for environmental issues during the reporting period, demonstrating compliance with environmental regulations[133] Future Outlook and Strategic Plans - The company plans to strengthen its marketing network and optimize its marketing organization to enhance overall performance in 2022[78] - The company aims to leverage existing resources through contract manufacturing to transition products from reserve to market-ready[78] - The company plans to continue expanding its market presence and product offerings in the future[114] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 100 million yuan allocated for potential deals[104] Shareholder Structure and Transparency - The company’s shareholder structure remained stable, with no significant changes in asset and liability structure reported[173] - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, totaling 129,348,530 shares[175] - The company has a total of 132,792,449 shares held by its directors and senior management, with some changes in shareholding during the reporting period[95] - The company is implementing a rectification plan to resolve the proxy shareholding issue, aiming for a swift resolution[178]

Financial Performance - The company's revenue for Q3 2021 was ¥218,657,311.81, representing a year-on-year increase of 0.71%[4] - The net profit attributable to shareholders for Q3 2021 was ¥23,880,406.66, an increase of 11.88% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥23,991,300.85, up 56.76% year-on-year[4] - Total operating revenue for Q3 2021 reached CNY 673,541,386.30, an increase of 9.7% compared to CNY 614,016,426.03 in the same period last year[20] - Operating profit for the period was CNY 88,409,326.92, up from CNY 77,844,776.38, reflecting a growth of 13.4% year-over-year[22] - Net profit attributable to the parent company was CNY 65,251,454.52, representing a 20.4% increase from CNY 54,188,768.07 in the previous year[22] - The company reported a basic earnings per share of CNY 0.1972, compared to CNY 0.1637 in the same quarter last year, marking a 20.4% increase[23] - The basic earnings per share for Q3 2021 was ¥0.0722, an increase of 11.94% compared to the same period last year[4] Cash Flow - The cash flow from operating activities for the year-to-date period reached ¥163,004,140.39, reflecting a significant increase of 101.25%[4] - The net cash flow from operating activities for Q3 2021 was ¥163,004,140.39, a significant increase of 101.01% compared to ¥80,995,109.69 in Q3 2020[26] - Cash inflow from operating activities totaled CNY 823,066,466.86, an increase from CNY 698,939,437.12 in the previous year, indicating a growth of 17.8%[24] - Cash outflows related to operating activities totaled ¥660,062,326.47, an increase of 6.73% from ¥617,944,327.43 in Q3 2020[26] - The net cash flow from investing activities was -¥100,684,903.68, a decline from -¥5,049,230.35 in the same period last year, indicating increased investment outflows[26] - Cash inflows from financing activities totaled ¥397,450,000.00, while cash outflows were ¥463,348,484.84, resulting in a net cash flow of -¥65,898,484.84 for Q3 2021[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,782,434,606.37, a decrease of 0.49% from the end of the previous year[4] - The company's total current assets as of September 30, 2021, amount to ¥2,166,911,877.68, a decrease from ¥2,223,356,178.91 at the end of 2020[18] - The total assets of the company as of September 30, 2021, are ¥2,782,434,606.37, slightly down from ¥2,796,099,005.75 at the end of 2020[18] - Total liabilities amounted to CNY 614,470,617.15, a decrease from CNY 663,864,893.91 at the end of the previous period[20] - Total liabilities stood at ¥663,864,893.91, remaining consistent with the previous year, which suggests effective liability management[31] Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,677[12] - Zhang Yisheng holds 39.08% of shares, totaling 129,348,530 shares, with 97,011,397 shares under lock-up conditions[12] - The company's equity attributable to shareholders increased by 2.77% to ¥2,051,040,844.15 compared to the end of the previous year[4] - The company's equity attributable to shareholders was ¥1,995,717,937.63, reflecting stability in shareholder value compared to the previous year[31] Investment and Development - The company reported a significant increase of 246.56% in construction in progress, amounting to ¥93,827,462.31, due to increased investment in the cosmetics deep processing industry project[9] - Research and development expenses for the quarter were CNY 14,891,356.12, slightly up from CNY 14,423,381.56, indicating continued investment in innovation[20] - The company has ongoing discussions regarding potential market expansion and new product development strategies[13] Financial Management - Financial expenses decreased by 41.90% to ¥4,482,915.62, primarily due to increased interest from agreement deposits[9] - The company has adopted new leasing standards starting in 2021, which may impact future financial reporting and asset management strategies[28] - The third quarter report for 2021 was not audited, which may affect the reliability of the financial data presented[32] Inventory and Receivables - The company's inventory as of September 30, 2021, is ¥1,609,706,267.63, compared to ¥1,615,762,224.99 at the end of 2020[18] - The company reported accounts receivable of ¥207,843,199.78 as of September 30, 2021, up from ¥205,229,958.10 at the end of 2020[18]